PfSPZ-Cvac – Sanaria

SANARIA VACCINE TRIAL RESULTS DEMONSTRATE UNPRECEDENTED PROGRESS IN WORLDWIDE BATTLE AGAINST VARIANT MALARIA PARASITES

June 30, 2021 By Alexander Hoffman In Press Releases No Comments

In an article published today in Nature, Sanaria’s PfSPZ-CVac (CQ) vaccine is reported as being safe and protecting 100% of six subjects against a variant malaria parasite three months after their last dose in the company’s Phase 1 safety and efficacy trial. This is the first time complete protection against a variant malaria parasite has ever been achieved that long after vaccine administration.

Optimizing immunization with Sanaria® PfSPZ-CVac malaria vaccine

June 8, 2021 By Alexander Hoffman In Press Releases No Comments

Sanaria and its collaborators have had to take a step by step empirical approach to optimizing immunization with PfSPZ vaccines to achieve a safe, effective, durable, and broadly protective malaria vaccine. Two recent landmark malaria vaccine studies have moved the optimization process forward and highlighted the strong protective efficacy of Sanaria® PfSPZ-CVac in malaria-naïve adults.

Teams From the Universtiy of Bamako, Mali and the NIH Visit Sanaria

April 25, 2019 By Alexander Hoffman In News No Comments

Teams from the Bamako Malaria Research Training Center, University of Bamako, Mali and the Laboratory of Immunology and Vaccinology, National Institutes of Allergy and Infectious Diseases, NIH visited Sanaria to discuss progress on our collaboration on 5 clinical trials in Mali and 2 clinical trials in the U.S. of PfSPZ Vaccine and PfSPZ-CVac.